-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ovarian cancer mainly occurs in women aged 50-70.
Ovarian cancer
Biopharmaceutical company Celsion today announced the latest information on the I/II OVATION 2 study of GEN-1 for the treatment of advanced ovarian cancer.
immunity
The OVATION 2 study explored the effectiveness and safety of GEN-1 combined with standard new adjuvant chemotherapy (NACT) in the treatment of newly treated stage III/IV ovarian cancer.
The results of the OVATION 2 study showed that compared with the control group (standard of care only), the treatment group (standard of care + GEN-1) increased the patient’s progression-free survival by 33%.
The results of the OVATION 2 study showed that compared with the control group (standard of care only), the treatment group (standard of care + GEN-1) increased the patient’s progression-free survival by 33%.
Original source:
Original source:https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here